2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2782

Not Only 5 but Also 6 Weeks Intervals of Tocilizumab Infusion Induce Clinical Remission in Patients with Active Rheumatoid Arthritis
Abstract Number: 2792

Not Only Sjögren’s Syndrome. EBV Infection Reactivation As a Risk Factor of the Dryness Symptome Development
Abstract Number: 901

Novel B Cell-Derived Peptide Regulation of Homeostatic T-Cell Trafficking Is Subverted in Rheumatoid Arthritis
Abstract Number: 1150

Novel Chitosan Hydrogels for the Treatment of Osteoarthritis: Mechanical Support, Lubrication and Prevention of Cartilage Degradation in a Rabbit Model of Osteoarthritis
Abstract Number: 1033

Novel Ligand-Independent Peptide Inhibitors of Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) and T Cell Receptor (TCR): Efficacy in a Collagen-Induced Arthritis Model Suggests New Targeted Treatment for Rheumatoid Arthritis
Abstract Number: 1813

Novel Mechanism of Action of Anti-Malarial Drugs in the Inhibition of Type I Interferon Production
Abstract Number: 2773

Novel Mechanisms of Action for Methotrexate and Doxycycline: Prevention of Protein Adduct Formation and Free Radical Scavenging
Abstract Number: 2566

Novel Therapeutic Compound Tuftsin-Phosphorylcholine Attenuate Collagen Induced Arthritis
Abstract Number: 946

Novel Tripartite Motif Proteins Linked to Membrane Integrity As Biomarkers of Dermatomyositis and Polymyositis
Abstract Number: 2988

Novel Use of Musculoskeletal Ultrasound (MSUS) to Measure Ulcers in the Skin of Systemic Sclerosis (SSc) Patients.
Abstract Number: 2564

Nuclear Receptor 4A2 Is Selectively Upregulated in the Human TNF-Alpha Transgenic Model of Rheumatoid Arthritis
Abstract Number: 1021

Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus
Abstract Number: 1000

Obesity and Foot Problems in the Framingham Foot Study: Does Foot Structure or Foot Function Protect Against Hallux Valgus?
Abstract Number: 1699

Obesity and Pediatric Psoriatic Arthritis
Abstract Number: 1598

Obesity and the Risk for Development of Rheumatoid Arthritis – Results from a Population-Based Nested Case-Control Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].